Vaishali Pharma is a pharmaceutical trading house that connects Indian manufacturers to healthcare buyers across more than 40 countries - it does not own factories but instead sources finished medicines, raw materials and surgical supplies from a network of outsourced production partners, earning its margin on the spread between what it buys and what it sells. The business began in 1989 as a Mumbai proprietorship trading in Active Pharmaceutical Ingredients, or APIs (the chemical building blocks of medicines), and has since expanded outward into branded formulations, veterinary products, nutraceuticals and oncology drugs, all while staying true to its original model of marketing products made by others. That recurring approach - build a portfolio of registrations and dossiers in far-flung markets, then fulfil orders through a qualified supplier base without tying up capital in plant and machinery - explains how a company with a single warehouse in Bhiwandi can serve customers from Russia to Peru. # Business segments A single trading-and-marketing engine that spans APIs, finished-dose formulations, surgical products, veterinary supplements and consumer nutraceuticals - all sourced from third-party manufacturers and sold into domestic and international markets through one order-driven platform. ## 1. Pharmaceutical trading and marketing: the core sourcing-and-supply engine **The company earns its revenue by buying healthcare products from WHO-approved contract manufacturers and reselling them to hospitals, corporates, retail stores and multinational pharma companies, taking title to the goods but not making them.** - **APIs are the backbone** - trading in bulk drugs and pharmaceutical raw materials forms roughly 70% of total revenue, supplying the active chemical ingredients that other drugmakers use in their own finished medicines, with customers that include multinational companies and large Indian corporations. - **Formulations add the margin layer** - the remaining 30% of revenue comes from marketing finished-dose products (tablets, capsules, injections, syrups) under the company’s own 250-plus brands, each backed by a CTD-format dossier with bioequivalence data that proves the copy works the same as the original. - **A portfolio built for breadth, not depth** - the company maintains roughly 400 products for the domestic market and more than 1,000 for export, spanning human medicines, surgical devices, veterinary supplements and oncology injections, so no single product or therapy area dominates the order book. - **Revenue recognised on shipment** - the company books a sale when control of goods passes to the customer, net of returns and trade discounts, and accrues export benefits in the year goods are shipped provided collection is reasonably certain. ## 2. International markets and regulatory access: the moat built on paper **Before a single tablet can be sold in most emerging markets, the product must be registered with the local health ministry - and Vaishali has already secured over 250 approvals across 35-plus countries, with another 200 applications in the pipeline.** - **Registrations are the entry ticket** - each country requires its own product-by-product approval, and the company navigates these rules and documentation requirements to open doors that competitors without dossiers cannot walk through. - **Sixty percent of sales come from exports** - the international footprint spans Asia, Africa, the CIS region and Latin America, with specific exposure to markets including Russia, UAE, Nigeria, Kenya, Sri Lanka, Ukraine, Ethiopia, Iraq, Lebanon, Myanmar, Bangladesh, Kazakhstan, Yemen, Cambodia, Tanzania, Vietnam and Peru. - **Strategic partnerships in hard-to-reach places** - the company has distribution alliances in the Democratic Republic of Congo, Kenya and Russia, and within two years became one of the leading players in Russia’s veterinary product segment, showing it can build a position quickly once registrations are in hand. - **Certifications that signal quality** - the company holds ISO 9001:2015 for quality management, ISO 13484:2016 and CE certification for surgical products, and multiple country-specific formulation certifications from Ethiopia, Kazakhstan and Oman, all of which reassure overseas regulators and buyers. ## 3. Nutraceutical, herbal and consumer brands: the front-end bet on branded wellness **Through marketing-rights deals with specialist manufacturers and the launch of its own direct-to-consumer brand, the company is trying to build a higher-margin, brand-driven layer on top of its commodity trading business.** - **Acquired marketing portfolios, not factories** - in 2022 the company signed agreements to take over the entire domestic and international marketing of Sankalp LifeCare’s 100-plus nutraceutical products (made in a USFDA-approved, WHO-compliant facility in Ahmedabad) and Jark Pharma’s range of Ayurvedic medicines and herbal cosmetics, giving it ready-made product lines without construction risk. - **Dosage forms that match the category** - the nutraceutical range spans tablets, effervescent tablets, chewable tablets, capsules, powders, sachets, liquids and gummies, plus spray formats for specific vitamins like Folic Acid + B12 and Vitamin D3, covering the formats consumers actually prefer. # Group structure and partners **A promoter-led single entity with a concentrated shareholding, now in the process of acquiring its first manufacturing subsidiary to bring production in-house for the first time.** - **Founder at the helm** - Chairman and Managing Director Mr. Atul Vasani holds 21.1% of the equity, and the top ten shareholders together control roughly 45%, making it a closely held public company. - **A six-member board with three independents** - the Board comprises three executive directors (including the CMD) and three independent directors, supported by a CEO, CFO and Company Secretary. - **The Kesar Pharma acquisition changes the asset-light model** - in February 2025 the Board approved a deal to acquire a 51% stake in Kesar Pharma Limited, an Ahmedabad-based manufacturer of pharmaceutical formulations, for approximately ₹20.4 crore, paid partly in cash and partly through fresh Vaishali shares; upon completion Kesar becomes a subsidiary, giving the company its first owned manufacturing capability. - **A related-party supplier in the background** - the company has a related party, Arochem Industries, in which the Chairman holds a 25% partnership interest.